Dai ichi Life Insurance Company Ltd Has $3.43 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Dai ichi Life Insurance Company Ltd grew its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 308.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 66,197 shares of the biopharmaceutical company’s stock after acquiring an additional 50,000 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Bristol-Myers Squibb were worth $3,425,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of BMY. Kennedy Capital Management LLC acquired a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $2,588,000. Ancora Advisors LLC grew its stake in shares of Bristol-Myers Squibb by 9.8% in the first quarter. Ancora Advisors LLC now owns 40,938 shares of the biopharmaceutical company’s stock valued at $2,220,000 after buying an additional 3,654 shares in the last quarter. Hancock Whitney Corp increased its holdings in Bristol-Myers Squibb by 5.9% during the first quarter. Hancock Whitney Corp now owns 24,555 shares of the biopharmaceutical company’s stock worth $1,332,000 after buying an additional 1,365 shares during the last quarter. Jaffetilchin Investment Partners LLC raised its position in Bristol-Myers Squibb by 9.8% during the first quarter. Jaffetilchin Investment Partners LLC now owns 10,265 shares of the biopharmaceutical company’s stock worth $557,000 after acquiring an additional 912 shares in the last quarter. Finally, iA Global Asset Management Inc. lifted its stake in Bristol-Myers Squibb by 2.3% in the first quarter. iA Global Asset Management Inc. now owns 114,573 shares of the biopharmaceutical company’s stock valued at $6,213,000 after acquiring an additional 2,623 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analysts Set New Price Targets

BMY has been the topic of several recent analyst reports. Cantor Fitzgerald restated a “neutral” rating and set a $50.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. Daiwa America upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Wolfe Research assumed coverage on Bristol-Myers Squibb in a research note on Friday, November 15th. They set a “peer perform” rating for the company. Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and increased their price target for the company from $55.00 to $73.00 in a research note on Tuesday, November 12th. Finally, Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $54.07.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Samit Hirawat acquired 1,830 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were acquired at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the purchase, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at $3,395,499.03. The trade was a 3.04 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Stock Down 0.1 %

Shares of BMY opened at $58.73 on Wednesday. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08. The firm’s 50 day moving average is $54.02 and its 200-day moving average is $47.97. The stock has a market capitalization of $119.11 billion, a PE ratio of -16.36, a P/E/G ratio of 15.79 and a beta of 0.44. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.26 billion. During the same period last year, the firm earned $2.00 earnings per share. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. Equities research analysts forecast that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.09%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -66.85%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.